当前位置：
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson’s Disease
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2023-05-29 , DOI: 10.1021/acs.jmedchem.3c00235 Tommi P Kilpeläinen , Henri T Pätsi , Reinis Svarcbahs , Ulrika H Julku , Tony S Eteläinen , Hengjing Cui 1 , Samuli Auno , Nina Sipari 2 , Susanna Norrbacka , Teppo O Leino , Maria Jäntti , Timo T Myöhänen 1 , Erik A A Wallén
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2023-05-29 , DOI: 10.1021/acs.jmedchem.3c00235 Tommi P Kilpeläinen , Henri T Pätsi , Reinis Svarcbahs , Ulrika H Julku , Tony S Eteläinen , Hengjing Cui 1 , Samuli Auno , Nina Sipari 2 , Susanna Norrbacka , Teppo O Leino , Maria Jäntti , Timo T Myöhänen 1 , Erik A A Wallén
Affiliation
|
Prolyl oligopeptidase (PREP) is a widely distributed serine protease in the human body cleaving proline-containing peptides; however, recent studies suggest that its effects on pathogenic processes underlying neurodegeneration are derived from direct protein–protein interactions (PPIs) and not from its regulation of certain neuropeptide levels. We discovered novel nonpeptidic oxazole-based PREP inhibitors, which deviate from the known structure–activity relationship for PREP inhibitors. These new compounds are effective modulators of the PPIs of PREP, reducing α-synuclein (αSyn) dimerization and enhancing protein phosphatase 2A activity in a concentration–response manner, as well as reducing reactive oxygen species production. From the best performing oxazoles, HUP-55 was selected for in vivo studies. Its brain penetration was evaluated, and it was tested in αSyn virus vector-based and αSyn transgenic mouse models of Parkinson’s disease, where it restored motor impairment and reduced levels of oligomerized αSyn in the striatum and substantia nigra.
中文翻译：
基于非肽恶唑的脯氨酰寡肽酶配体对帕金森病 α-突触核蛋白小鼠模型具有疾病缓解作用
脯氨酰寡肽酶（PREP）是人体内广泛分布的丝氨酸蛋白酶，可裂解含脯氨酸的肽；然而，最近的研究表明，它对神经退行性病变致病过程的影响源自直接的蛋白质-蛋白质相互作用（PPI），而不是来自其对某些神经肽水平的调节。我们发现了新型非肽类恶唑类 PREP 抑制剂，它偏离了 PREP 抑制剂已知的构效关系。这些新化合物是 PREP 的 PPI 的有效调节剂，以浓度响应方式减少 α-突触核蛋白 (αSyn) 二聚化并增强蛋白磷酸酶 2A 活性，并减少活性氧的产生。从性能最好的恶唑中，选择HUP-55进行体内研究学习。我们评估了它的大脑渗透性，并在基于 αSyn 病毒载体和帕金森病 αSyn 转基因小鼠模型中进行了测试，它恢复了运动障碍并降低了纹状体和黑质中寡聚 αSyn 的水平。
更新日期：2023-05-29
中文翻译：
基于非肽恶唑的脯氨酰寡肽酶配体对帕金森病 α-突触核蛋白小鼠模型具有疾病缓解作用
脯氨酰寡肽酶（PREP）是人体内广泛分布的丝氨酸蛋白酶，可裂解含脯氨酸的肽；然而，最近的研究表明，它对神经退行性病变致病过程的影响源自直接的蛋白质-蛋白质相互作用（PPI），而不是来自其对某些神经肽水平的调节。我们发现了新型非肽类恶唑类 PREP 抑制剂，它偏离了 PREP 抑制剂已知的构效关系。这些新化合物是 PREP 的 PPI 的有效调节剂，以浓度响应方式减少 α-突触核蛋白 (αSyn) 二聚化并增强蛋白磷酸酶 2A 活性，并减少活性氧的产生。从性能最好的恶唑中，选择HUP-55进行体内研究学习。我们评估了它的大脑渗透性，并在基于 αSyn 病毒载体和帕金森病 αSyn 转基因小鼠模型中进行了测试，它恢复了运动障碍并降低了纹状体和黑质中寡聚 αSyn 的水平。
京公网安备 11010802027423号